Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Opioid Labeling: Congress Wants Box Warning On Immediate-Release Products

This article was originally published in The Pink Sheet Daily

Executive Summary

House Energy & Commerce Committee asks FDA to explain discrepancy in labeling between immediate release and extended release/long-acting formulations, questions effectiveness of opioid REMS.


Related Content

Opioid Indication Change Could Draw Legal Challenge From Physicians Group Seeking More Restrictions